The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

It’s also an industry that could come crashing down the moment the Food ... The shortages rarely apply to blockbuster drugs, ...

The GLP-1 drugmaker recorded $26.0M of net income compared to only $1.2M in Q4 2023, thanks mainly to a ~95% YoY rise in its revenue, which reached $481.1M, exceeding the consensus by $10.6M.